RxDoctor Payments Data

Eric Kozfkay, DO

Pain Medicine · Wyoming, MINPI 1497710610

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Arthrex accounts for 68.8% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $14,573 and has fallen 97.5% since, to $357 in 2025. Among pain medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,180in general payments, 2019–2025

Across 227 payments — averaging $88.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$14K
  • Vertos Medical, Inc.$2K
  • Boston Scientific$1K
  • Relievant Medsystems, Inc.$375
  • Abbott$340
  • Nevro Corp.$266
  • plus $2K from 25 others
$7,933in research payments, 2019–2025

Across 7 payments — averaging $1133.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$7K
  • Scilex Pharmaceuticals Inc.$500

What the payments were for

  • Consulting fees$2,10010%
  • Speaking & faculty fees$11,78858%
  • Food & beverage$6,29231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,180 in reported general payments places this provider in the 90th percentile of 139 pain medicine providers in Michigan.

See all pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$69,491
Medicare patients
120
Services billed
2,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm18$11,945
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen526$7,913
Oxymorphone Hcl ErOxymorphone Hcl14$7,069
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen292$5,193
Buprenorphine15$4,139
Fentanyl32$3,374
Gabapentin249$2,822
Pregabalin49$2,621
Morphine Sulfate ErMorphine Sulfate73$2,491
Methadone Hcl79$1,743
Oxycodone Hcl53$1,294
Tramadol Hcl151$945
Metaxalone11$868
Tramadol Hcl ErTramadol Hcl15$765
Methocarbamol50$630

Paid to pharmacies, not to this prescriber.

Other pain medicine in Wyoming

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →